Higher AP1M2 expression indicated poorer prognosis of tumor patients by the survival analysis of BRCA, while AP1M2 expression levels were negatively correlated with B cells, T cells (CD4+ and CD8+), macrophages, neutrophils, DC infiltration, and scores of the immune system, stromal, and composites via immune analysis. Here, CD8A is linked to neoplasm.